A Phase 1 interventional study of Roluperidone 64 mg and Olanzapine 10 MG in Negative Symptoms in Schizophrenia, sponsored by Minerva Neurosciences. Completed at 3 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Minerva Neurosciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.
Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 1,142nd largest by enrollment of the 1,319 interventional ones that give a count, is one of 40 that started in 2023, is one of 196 in phase 1, and was the 1,336th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–55
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,465 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 271 · Phase 3 218 · Phase 4 193
First in 1983; this study’s year is marked. 40 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 1,319 interventional studies, 163 across the 128 observational. Of the 1,234 that completed or were terminated, 603 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
517 of 1,465 have an industry lead sponsor. The 10 most frequent:
Minerva Neurosciences is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Minerva Neurosciences has 4 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
52 of the studies in Schizophrenia with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07363577Phase 3LB Pharmaceuticals Inc.Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | 2027-06 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,465 studies in Schizophrenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects with Moderate to Severe Negative Symptoms of Schizophrenia.
The main question this clinical trial aims to answer are the pharmacodynamic and pharmacokinetic effects and safety of the concomitant therapy of Roluperidone with an established and widely used antipsychotic, such as olanzapine in order to provide further guidance to clinical practitioners that may prescribe off-label use of these drugs concomitantly in clinical practice.
Eligible Participants will undergo the following study phases in the clinic:
End of Study (EOS): Will take place at least 14 days after the last dose of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PANSS item score of > 4 on:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roluperidone 64 mg monotherapy administered as an oral dose daily for 7 days on Days 1-7.
Drug: Roluperidone 64 mg
Roluperidone 64 mg oral and olanzapine 10 mg oral administered at the same time daily for 10 days on Days 8-17.
Drug: Roluperidone 64 mg · Drug: Olanzapine 10 MG
64 mg/day oral
Also known as: MIN-101
10 mg/day oral
Extrapyramidal Symptoms Assessed by Abnormal Involuntary Movement Scale (AIMS) - Change From Baseline in AIMS Component Movement
AIMS is a rating scale to measure tardive dyskinesia (TD). For the scoring, the AIMS scale has 14 items. The first 10 items (under categories of Facial and Oral Movements, Extremity Movements, Trunk Movements, and Global Judgements) are rated from 0 (none) to 4 (severe); the remaining 4 items (Dental Status) are rated "yes" and "no" and not counted. The analysis is limited to items 1 to 10, with each rated from 0 to 4. The total score is the sum of all 10 items and with values ranging from 0 to 40. Overall change from baseline to End of Study (Day 17) in AIMS was reported for the Safety Set. Higher scores imply worse outcome.
Time frame: Overall - Change from Baseline to End of Study (Day 17)
Barnes Akathisia Rating Scale (BARS)
BARS is a multiple-choice questionnaire that clinicians may use to provide an assessment of akathisia. The clinician or rater is instructed to observe the subject while standing and while sitting, at least 2 minutes each (total of at least 4 minutes in total). There are 4 areas where the subject is to be evaluated, 1 of these is objective, 2 are subjective, and the final is a global assessment. The BARS scale has 3 items that are rated from 0 (absence/no distress) to 3 (most severe). The BARS rating scale is scored by summing the scales for Objective Akathisia, Subjective Awareness of Restlessness and Subjective Distress Related to Restlessness yielding a total score ranging from 0 to 9. The Total score, which has a possible range from 0-9, is reported. Higher scores imply worse outcome.
Time frame: Overall - Change from Baseline to End of Study (Day 17)
Number of Subjects Who Experienced Suicidal Ideation or Behavior Events Per the Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a measure to identify and assess individuals at risk for suicide. Questions are phrased for an interview format but can be completed as a self-report measure if needed. It measures 4 constructs: severity of ideation, intensity of ideation, behavior, and lethality. It includes "stem questions," which if endorsed, prompt additional follow-up questions to obtain more information. For the composite endpoint of suicidal ideation or behavior (1-10), the number and percent of subjects in the Overall Safety Set who experience any one of the ten suicidal ideation or behavior events at End of Study (Day 17).
Time frame: Overall - End of Study (Day 17)
Pharmacokinetic Evaluation of Roluperidone - Maximum Plasma Concentration (Cmax)
Cmax of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.
Time frame: Days 1 through 17
Pharmacokinetic Evaluation of Roluperidone - Time to Maximum Plasma Concentration (Tmax)
Tmax of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.
Time frame: Days 1 through 17
Pharmacokinetic Evaluation of Roluperidone - Area Under the Plasma Concentration Versus Time Curve (AUC 0-24)
AUC of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.
Time frame: Days 1 through 17
Pharmacokinetic Evaluation of Roluperidone - Area Under the Plasma Concentration Versus Time Curve (AUC Inf)
AUC of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.
Time frame: Days 1 through 17
Plasma PK Parameter for Olanzapine Cmax
Cmax of olanzapine administered concomitantly with roluperidone
Time frame: Treatment Phase 2 (Day 8 through Day 17)
Plasma PK Parameter for Olanzapine Tmax
Tmax of olanzapine administered concomitantly with roluperidone
Time frame: Treatment Phase 2 (Day 8 through Day 17)
Plasma PK Parameter for Olanzapine AUC 0-24
AUC 0-24 olanzapine administered concomitantly with roluperidone
Time frame: Treatment Phase 2 (Day 8 through Day 17)
Plasma PK Parameter for Olanzapine AUC Inf
AUC inf olanzapine administered concomitantly with roluperidone
Time frame: Treatment Phase 2 (Day 8 through Day 17)
Pharmacokinetic Evaluation of Co-administration Versus Roluperidone Monotherapy - Maximum Plasma Concentration (Cmax)
Comparison of roluperidone on Day 17 with olanzapine to roluperidone alone on Day 7 for Cmax. The geometric mean and geometric coefficient of variation are reported for the analytes roluperidone and its metabolite.
Time frame: Days 1 through 17
Pharmacokinetic Evaluation of Co-administration - AUC 0-24
Comparison of roluperidone on Day 17 with olanzapine to roluperidone alone on Day 7 for AUC 0-24. The geometric mean and geometric coefficient of variation are reported for the analytes roluperidone and its metabolite.
Time frame: Days 1 through 17
| Milestone | Overall Safety Set |
|---|---|
| Started | 17 |
| Full set | 17 |
| Safety set | 17 |
| Pharmacokinetic set | 12 |
| Pharmacokinetic completer set | 11 |
| Completed | 13 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Protocol violation | 1 |
AIMS is a rating scale to measure tardive dyskinesia (TD). For the scoring, the AIMS scale has 14 items. The first 10 items (under categories of Facial and Oral Movements, Extremity Movements, Trunk Movements, and Global Judgements) are rated from 0 (none) to 4 (severe); the remaining 4 items (Dental Status) are rated "yes" and "no" and not counted. The analysis is limited to items 1 to 10, with each rated from 0 to 4. The total score is the sum of all 10 items and with values ranging from 0 to 40. Overall change from baseline to End of Study (Day 17) in AIMS was reported for the Safety Set. Higher scores imply worse outcome.
| score on a scale | Overall Safety Set |
|---|---|
| Extrapyramidal Symptoms Assessed by Abnormal Involuntary Movement Scale (AIMS) - Change From Baseline in AIMS Component Movement | 0.0 ± 0.00 |
BARS is a multiple-choice questionnaire that clinicians may use to provide an assessment of akathisia. The clinician or rater is instructed to observe the subject while standing and while sitting, at least 2 minutes each (total of at least 4 minutes in total). There are 4 areas where the subject is to be evaluated, 1 of these is objective, 2 are subjective, and the final is a global assessment. The BARS scale has 3 items that are rated from 0 (absence/no distress) to 3 (most severe). The BARS rating scale is scored by summing the scales for Objective Akathisia, Subjective Awareness of Restlessness and Subjective Distress Related to Restlessness yielding a total score ranging from 0 to 9. The Total score, which has a possible range from 0-9, is reported. Higher scores imply worse outcome.
| score on a scale | Overall Safety Set |
|---|---|
| Barnes Akathisia Rating Scale (BARS) | 0.0 ± 0.00 |
C-SSRS is a measure to identify and assess individuals at risk for suicide. Questions are phrased for an interview format but can be completed as a self-report measure if needed. It measures 4 constructs: severity of ideation, intensity of ideation, behavior, and lethality. It includes "stem questions," which if endorsed, prompt additional follow-up questions to obtain more information. For the composite endpoint of suicidal ideation or behavior (1-10), the number and percent of subjects in the Overall Safety Set who experience any one of the ten suicidal ideation or behavior events at End of Study (Day 17).
| Participants | Overall Safety Set |
|---|---|
| Number of Subjects Who Experienced Suicidal Ideation or Behavior Events Per the Columbia Suicide Severity Rating Scale (C-SSRS) | 0 |
Cmax of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.
| ng/ml | Overall Safety Set - Roluperidone | Overall Safety Set - Metabolite BFB-520 |
|---|---|---|
| Treatment Phase 1 - Day 1 | 32.5 ± 13.7 | 5.00 ± 5.69 |
| Treatment Phase 1 - Day 7 | 43.6 ± 19.9 | 7.98 ± 6.78 |
| Treatment Phase 2 - Day 17 | 67.7 ± 28.6 | 12.2 ± 12.9 |
Tmax of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.
| hr | Overall Safety Set - Roluperidone | Overall Safety Set - Metabolite BFB-520 |
|---|---|---|
| Treatment Phase 1 - Day 1 | 9.74 ± 7.37 | 16.2 ± 6.72 |
| Treatment Phase 1 - Day 7 | 7.47 ± 5.73 | 9.60 ± 6.02 |
| Treatment Phase 2 - Day 17 | 6.20 ± 4.56 | 8.76 ± 4.90 |
AUC of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.
| hr*ng/mL | Overall Safety Set - Roluperidone | Overall Safety Set - Metabolite BFB-520 |
|---|---|---|
| Treatment Phase 1 - Day 1 | 391 ± 252 | 52.3 ± 63.0 |
| Treatment Phase 1 - Day 7 | 507 ± 278 | 135 ± 122 |
| Treatment Phase 2 - Day 17 | 720 ± 321 | 203 ± 225 |
AUC of roluperidone and its metabolite following single dose and at steady state, and when administered concomitantly with olanzapine.
| hr*ng/mL | Overall Safety Set - Roluperidone | Overall Safety Set - Metabolite BFB-520 |
|---|---|---|
| Treatment Phase 1 - Day 1 | 338 ± 289 | 60.7 ± 82.0 |
| Treatment Phase 1 - Day 7 | 495 ± 272 | 168 ± 234 |
| Treatment Phase 2 - Day 17 | 883 ± 420 | 263 ± 280 |
Cmax of olanzapine administered concomitantly with roluperidone
| ng/ml | Treatment Phase 2 - Day 17 |
|---|---|
| Plasma PK Parameter for Olanzapine Cmax | 35.6 ± 12.7 |
Tmax of olanzapine administered concomitantly with roluperidone
| hr | Treatment Phase 2 - Day 17 |
|---|---|
| Plasma PK Parameter for Olanzapine Tmax | 4.11 ± 2.24 |
AUC 0-24 olanzapine administered concomitantly with roluperidone
| hr*ng/ml | Treatment Phase 2 - Day 17 |
|---|---|
| Plasma PK Parameter for Olanzapine AUC 0-24 | 587 ± 220 |
AUC inf olanzapine administered concomitantly with roluperidone
| hr*ng/ml | Treatment Phase 2 - Day 17 |
|---|---|
| Plasma PK Parameter for Olanzapine AUC Inf | 719 ± 144 |
Comparison of roluperidone on Day 17 with olanzapine to roluperidone alone on Day 7 for Cmax. The geometric mean and geometric coefficient of variation are reported for the analytes roluperidone and its metabolite.
| ng/ml | Reference - Roluperidone Alone on Day 7 | Test - Roluperidone With Olanzapine on Day 17 |
|---|---|---|
| Roluperidone Analyte | 39.8 ± 46.37 | 62.2 ± 44.78 |
| BFB-520 Analyte | 5.96 ± 89.12 | 8.54 ± 100.10 |
Comparison of roluperidone on Day 17 with olanzapine to roluperidone alone on Day 7 for AUC 0-24. The geometric mean and geometric coefficient of variation are reported for the analytes roluperidone and its metabolite.
| hr*ng/ml | Reference - Roluperidone Alone on Day 7 | Test - Roluperidone With Olanzapine on Day 17 |
|---|---|---|
| Roluperidone Analyte | 451 ± 50.50 | 656 ± 48.37 |
| BFB-520 Analyte | 95.7 ± 103.10 | 135 ± 107.95 |
Collected over Treatment through end of study (Day 17).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Phase 1 | 0/17 (0%) | 1/17 (5.9%) | 5/17 (29.4%) |
| Treatment Phase 2 | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| Event | Treatment Phase 1 | Treatment Phase 2 |
|---|---|---|
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/17 | 0/15 |
| Event | Treatment Phase 1 | Treatment Phase 2 |
|---|---|---|
| DizzinessNervous system disorders | 0/17 | 3/15 |
| SomnolenceNervous system disorders | 0/17 | 2/15 |
| HeadacheNervous system disorders | 2/17 | 0/15 |
| SyncopeNervous system disorders | 0/17 | 1/15 |
| Electrocardiogram T wave inversionInvestigations | 0/17 | 1/15 |
| PresyncopeNervous system disorders | 1/17 | 0/15 |
| Alanine aminotransferase increasedInvestigations | 1/17 | 0/15 |
| Blood creatine phosphokinase increasedInvestigations | 1/17 | 0/15 |
| Heart rate increasedInvestigations | 1/17 | 0/15 |
| AgitationPsychiatric disorders | 1/17 | 0/15 |
| Age, Continuous(Years) | Overall Safety Set |
|---|---|
| Mean | 36.3 ± 8.20 |
| Sex: Female, Male(Participants) | Overall Safety Set |
|---|---|
| Female | 2 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Overall Safety Set |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 12 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Safety Set |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 8 |
| White | 8 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Overall Safety Set |
|---|---|
| United States | 17 |
| Body Mass Index at Baseline(kg/m2) | Overall Safety Set |
|---|---|
| Mean | 27.3 ± 4.58 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2023 to primary completion in Jan 2024, 2 months.
Results were first posted in Mar 2025, 1 year 2 months after primary completion.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 2 months is below that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roluperidone
Minerva Neurosciences